TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Bonnefoi, H.; Piccart, M.; Bogaerts, J.; Mauriac, L.; Fumoleau, P.; Brain, E.; Petit, T.; Rouanet, P.; Jassem, J.; Blot, E.; Zaman, K.; Cufer, T.; Lortholary, A.; Lidbrink, E.; André, S.; Litière, S.; Lago, L.D.; Becette, V.; Cameron, D.A.; Bergh, J.; Iggo, R.

doi:10.1016/S1470-2045(11)70094-8

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Détails

Télécharger: 21570352_Postprint.pdf (1504.67 [Ko])
Etat: Public
Version: de l'auteur⸱e

ID Serval

serval:BIB_EC7CF00354A2

Type

Article: article d'un périodique ou d'un magazine.

Collection

Publications

Institution

UNIL/CHUV

Titre

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Périodique

Lancet Oncology

Auteur⸱e⸱s

Bonnefoi H., Piccart M., Bogaerts J., Mauriac L., Fumoleau P., Brain E., Petit T., Rouanet P., Jassem J., Blot E., Zaman K., Cufer T., Lortholary A., Lidbrink E., André S., Litière S., Lago L.D., Becette V., Cameron D.A., Bergh J., Iggo R.

Collaborateur⸱rice⸱s

EORTC 10994/BIG 1-00 Study Investigators

ISSN

1474-5488 (Electronic)

ISSN-L

1470-2045

Statut éditorial

Publié

Date de publication

2011

Volume

12

Numéro

6

Pages

527-539

Langue

anglais

Notes

Publication types: Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov'tPublication Status: ppublish

Mots-clé

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Breast Neoplasms/chemistry, Breast Neoplasms/drug therapy, Female, Humans, Middle Aged, Mutation, Neoadjuvant Therapy, Receptor, erbB-2/analysis, Receptors, Estrogen/analysis, Taxoids/administration & dosage, Taxoids/therapeutic use, Tumor Suppressor Protein p53/genetics, Tumor Suppressor Protein p53/physiology

URN

urn:nbn:ch:serval-BIB_EC7CF00354A27

OAI-PMH

oai:serval.unil.ch:BIB_EC7CF00354A2

DOI

10.1016/S1470-2045(11)70094-8

Pubmed

21570352

Web of science

000291842400016

Open Access

Oui